FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016946327> ?p ?o ?g. }

• W3016946327 abstract "Abstract Objective: To investigate the effects of nicotinamide adenine dinucleotide (NAD+) on the pathogenesis of the animal model for multiple sclerosis (MS)-experimental autoimmune encephalomyelitis (EAE). Methods: EAE model was induced by myelin oligodendrocyte protein (MOG 35-55). Clinical scores of EAE were measured in mice with or without NAD+ treatment. Hematoxylin and Eosin (HE) and Luxol Fast Blue (LFB) staining were performed to assess inflammation and demyelination, respectively. Expressions of target proteins were measured by Western blot. The numbers of myeloid-derived suppressor cells (MDSCs) were measured by immunofluorescent staining and flow cytometry. Enzyme-linked immunosorbent assay (ELISA) was used to measure the expressions of inflammatory cytokine in serum. Results: NAD+ treatment could decrease inflammatory cells and demyelination foci, attenuate the clinical scores of EAE and slightly delay disease onset. Western blot showed that NAD+ treatment up-regulated the expression of phosphorylated-STAT6 (p-STAT6) and SIRT1. Besides, NAD+ treatment up-regulated the expression of p-IκB and down-regulated the expression of p-NF-κB. In addition, NAD+ treatment could increase the numbers of CD11b+ gr-1+ MDSCs and the expression of Arginase-1. Moreover, NAD+ treatment up-regulated the expressions of IL-13 and down-regulated the expression of IFN-γ and IL-17. Conclusions: The present study demonstrated that NAD+ treatment may induce the CD11b+ gr-1+ MDSCs to attenuate EAE via activating the phosphorylation of STAT6 expression. Therefore, NAD+ should be considered as a potential novel therapeutic strategy for MS." @default.
• W3016946327 created "2020-04-24" @default.
• W3016946327 creator A5003324584 @default.
• W3016946327 creator A5024349656 @default.
• W3016946327 creator A5025160966 @default.
• W3016946327 creator A5029695887 @default.
• W3016946327 creator A5054418515 @default.
• W3016946327 creator A5056924860 @default.
• W3016946327 creator A5061760088 @default.
• W3016946327 creator A5078176416 @default.
• W3016946327 creator A5084387104 @default.
• W3016946327 date "2020-04-01" @default.
• W3016946327 modified "2023-09-27" @default.
• W3016946327 title "NAD+ attenuates experimental autoimmune encephalomyelitis through induction of CD11b+ gr-1+ myeloid-derived suppressor cells" @default.
• W3016946327 cites W1536028944 @default.
• W3016946327 cites W1560571961 @default.
• W3016946327 cites W1693495046 @default.
• W3016946327 cites W1976843607 @default.
• W3016946327 cites W2002826439 @default.
• W3016946327 cites W2008586010 @default.
• W3016946327 cites W2012283308 @default.
• W3016946327 cites W2017332009 @default.
• W3016946327 cites W2034372375 @default.
• W3016946327 cites W2039619846 @default.
• W3016946327 cites W2060672294 @default.
• W3016946327 cites W2073387289 @default.
• W3016946327 cites W2075727474 @default.
• W3016946327 cites W2097813112 @default.
• W3016946327 cites W2104065243 @default.
• W3016946327 cites W2122934527 @default.
• W3016946327 cites W2143001254 @default.
• W3016946327 cites W2150076493 @default.
• W3016946327 cites W2490476022 @default.
• W3016946327 cites W2527725348 @default.
• W3016946327 cites W2549644306 @default.
• W3016946327 cites W2591762186 @default.
• W3016946327 cites W2713106898 @default.
• W3016946327 cites W2883757942 @default.
• W3016946327 cites W2893775836 @default.
• W3016946327 cites W2927917099 @default.
• W3016946327 cites W2945350265 @default.
• W3016946327 cites W2946579098 @default.
• W3016946327 cites W2966549733 @default.
• W3016946327 doi "https://doi.org/10.1042/bsr20200353" @default.
• W3016946327 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7182659" @default.
• W3016946327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32301489" @default.
• W3016946327 hasPublicationYear "2020" @default.
• W3016946327 type Work @default.
• W3016946327 sameAs 3016946327 @default.
• W3016946327 citedByCount "3" @default.
• W3016946327 countsByYear W30169463272023 @default.
• W3016946327 crossrefType "journal-article" @default.
• W3016946327 hasAuthorship W3016946327A5003324584 @default.
• W3016946327 hasAuthorship W3016946327A5024349656 @default.
• W3016946327 hasAuthorship W3016946327A5025160966 @default.
• W3016946327 hasAuthorship W3016946327A5029695887 @default.
• W3016946327 hasAuthorship W3016946327A5054418515 @default.
• W3016946327 hasAuthorship W3016946327A5056924860 @default.
• W3016946327 hasAuthorship W3016946327A5061760088 @default.
• W3016946327 hasAuthorship W3016946327A5078176416 @default.
• W3016946327 hasAuthorship W3016946327A5084387104 @default.
• W3016946327 hasBestOaLocation W30169463271 @default.
• W3016946327 hasConcept C104317684 @default.
• W3016946327 hasConcept C134018914 @default.
• W3016946327 hasConcept C153911025 @default.
• W3016946327 hasConcept C181199279 @default.
• W3016946327 hasConcept C185592680 @default.
• W3016946327 hasConcept C203014093 @default.
• W3016946327 hasConcept C2776415932 @default.
• W3016946327 hasConcept C2776901170 @default.
• W3016946327 hasConcept C2778486448 @default.
• W3016946327 hasConcept C2778609137 @default.
• W3016946327 hasConcept C2780640218 @default.
• W3016946327 hasConcept C529278444 @default.
• W3016946327 hasConcept C553184892 @default.
• W3016946327 hasConcept C55493867 @default.
• W3016946327 hasConcept C71924100 @default.
• W3016946327 hasConcept C75520062 @default.
• W3016946327 hasConcept C86803240 @default.
• W3016946327 hasConcept C90224389 @default.
• W3016946327 hasConceptScore W3016946327C104317684 @default.
• W3016946327 hasConceptScore W3016946327C134018914 @default.
• W3016946327 hasConceptScore W3016946327C153911025 @default.
• W3016946327 hasConceptScore W3016946327C181199279 @default.
• W3016946327 hasConceptScore W3016946327C185592680 @default.
• W3016946327 hasConceptScore W3016946327C203014093 @default.
• W3016946327 hasConceptScore W3016946327C2776415932 @default.
• W3016946327 hasConceptScore W3016946327C2776901170 @default.
• W3016946327 hasConceptScore W3016946327C2778486448 @default.
• W3016946327 hasConceptScore W3016946327C2778609137 @default.
• W3016946327 hasConceptScore W3016946327C2780640218 @default.
• W3016946327 hasConceptScore W3016946327C529278444 @default.
• W3016946327 hasConceptScore W3016946327C553184892 @default.
• W3016946327 hasConceptScore W3016946327C55493867 @default.
• W3016946327 hasConceptScore W3016946327C71924100 @default.
• W3016946327 hasConceptScore W3016946327C75520062 @default.
• W3016946327 hasConceptScore W3016946327C86803240 @default.
• W3016946327 hasConceptScore W3016946327C90224389 @default.
• W3016946327 hasIssue "4" @default.
• W3016946327 hasLocation W30169463271 @default.

• next